AstraZeneca PLC — Director's Dealing 2018

Oct 18, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PhaseBio Pharmaceuticals Inc (PHAS)
CIK: 0001169245
Period of Report: 2018-10-17

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: Zeneca, Inc. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C-1 Preferred Stock	$		Common Stock (1553060)		Indirect
Series D Preferred Stock	$		Common Stock (740337)		Indirect
Warrants to Purchase Series C-1 Preferred Stock	$0.12		Series C-1 Preferred Stock (113891)		Indirect

Footnotes

F1: Each share of Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

F2: Zeneca, Inc. is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the securities held by Zeneca, Inc., but disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, if any.

F3: The warrants are immediately exercisable and terminate upon the closing of the Issuer's initial public offering.